Stock Yards Bank & Trust Co. Has $1.30 Million Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Stock Yards Bank & Trust Co. cut its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 12.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,917 shares of the medical equipment provider’s stock after selling 430 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Intuitive Surgical were worth $1,298,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Advisors Asset Management Inc. grew its stake in shares of Intuitive Surgical by 18.1% in the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock valued at $2,945,000 after acquiring an additional 1,129 shares in the last quarter. Public Employees Retirement System of Ohio grew its stake in Intuitive Surgical by 5.4% during the fourth quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock worth $64,531,000 after buying an additional 9,869 shares in the last quarter. HCR Wealth Advisors grew its stake in Intuitive Surgical by 26.3% during the fourth quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock worth $352,000 after buying an additional 217 shares in the last quarter. Artisan Partners Limited Partnership grew its stake in Intuitive Surgical by 53.5% during the fourth quarter. Artisan Partners Limited Partnership now owns 63,851 shares of the medical equipment provider’s stock worth $21,541,000 after buying an additional 22,264 shares in the last quarter. Finally, SWP Financial LLC acquired a new stake in Intuitive Surgical during the fourth quarter worth about $255,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ISRG has been the topic of a number of analyst reports. Piper Sandler increased their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. The Goldman Sachs Group initiated coverage on shares of Intuitive Surgical in a research note on Thursday, May 30th. They set a “buy” rating and a $500.00 price objective on the stock. Morgan Stanley increased their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Citigroup increased their target price on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Finally, BTIG Research increased their target price on shares of Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $446.45.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the transaction, the director now owns 821 shares in the company, valued at approximately $402,519.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, EVP Myriam Curet sold 2,818 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the completion of the sale, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $136,522.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the sale, the director now directly owns 821 shares of the company’s stock, valued at approximately $402,519.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $483.32 on Wednesday. The company has a 50 day simple moving average of $465.50 and a 200 day simple moving average of $423.39. The firm has a market cap of $171.43 billion, a PE ratio of 87.24, a price-to-earnings-growth ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same quarter last year, the business earned $1.18 EPS. The company’s revenue was up 14.5% compared to the same quarter last year. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.